Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US0153511094
Ticker ALXN
Company ALEXION PHARMACEUTICALS
Currency $
Price
Aware Investor Index (AII) 0.0005
Recommendation STRONG SELL
P/E 97.06
ROE 3.09 %
Capitalization 26,714,408,000 $
Dividend Yield 0.00 %
P/S 7.52
AII Position 695
P/E Position 697
ROE Position 686
Capitalization Position 294
Dividend Yield Position 595
Sales 3,551,100,000 $
10-Year Average Earnings 275,237,400 $
Shares Outstanding 225,400,000
Equity 8,893,100,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country United States
ALEXION PHARMACEUTICALS Investor Relations Web Site http://ir.alexion.com/







Sales:

YEAR MONTH AMOUNT
2017 12 3,551,100,000.00 $
2016 12 3,084,100,000.00 $
2015 12 2,604,047,000.00 $
2014 12 2,233,733,000.00 $
2013 12 1,551,346,000.00 $
2012 12 1,134,114,000.00 $
2011 12 783,431,000.00 $
2010 12 540,957,000.00 $
2009 12 386,800,000.00 $
2008 12 259,099,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 443,300,000.00 $
2016 12 399,400,000.00 $
2015 12 144,385,000.00 $
2014 12 656,912,000.00 $
2013 12 252,895,000.00 $
2012 12 254,822,000.00 $
2011 12 175,315,000.00 $
2010 12 97,030,000.00 $
2009 12 295,166,000.00 $
2008 12 33,149,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 8,893,100,000.00 $
2016 12 8,693,800,000.00 $
2015 12 8,258,616,000.00 $
2014 12 3,302,018,000.00 $
2013 12 2,382,079,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 225,400,000
2016 12 226,300,000
2015 12 215,933,000
2014 12 201,623,000
2013 12 199,712,000

 












Bloomberg News for ALEXION PHARMACEUTICALS:



Google News for ALEXION PHARMACEUTICALS:

Seeking Alpha - 24 Oct 2018
Alexion Pharmaceuticals (ALXN) Q3 2018 Results - Earnings Call ...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q3 2018 Earnings Call October 24, 2018 8:00 AM ET. Executives. Susan Altschuller - Alexion ...
StreetInsider.com
Oppenheimer Reiterates “$165.00” Price Target for Alexion ...
Alexion Pharmaceuticals (NASDAQ:ALXN) has been given a $165.00 price objective by investment analysts at Oppenheimer in a research ...
Nasdaq
Alexion Pharmaceuticals: An Impressive Rare Disease Player At ...
Alexion Pharmaceuticals has revised upwards FY 2018 revenue guidance for Soliris franchise. Ultomiris or ALXN 1210 is expected to help ...
Motley Fool
Alexion Pharmaceuticals (ALXN): The Secrets of STOCK
Alexion Pharmaceuticals (ALXN) moved with down change of -3.92% at $118.6 during Monday trading period. This stock price move and price ...
Fairfield Current - 1 hour ago
Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical ...
As we can see, Alexion Pharmaceuticals is performing better than its sector in the calendar year. Breaking things down more, ALXN is a ...
Analyst Ratings
Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to ...
Alexion Pharmaceuticals (ALXN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...
Marea Informative (blog)
Alexion Pharmaceuticals, Inc. (ALXN) price is down -1.91% off its ...
Alexion Pharmaceuticals, Inc. (ALXN) price is down -1.91% off its 200- ... ALXN stock price revealed pessimistic move of -1.91% comparing ...
The RNS Daily
Focus on Momentum Mover: Alexion Pharmaceuticals, Inc. (ALXN)
Focus on Momentum Mover: Alexion Pharmaceuticals, Inc. (ALXN) ... ALXN reported a change of -3.81% over the last week and performed ...
Seeking Alpha - 31 Oct 2018
Alexion Pharmaceuticals (ALXN) to strike $163.29 in short term period
Alexion Pharmaceuticals (ALXN) stock managed performance -3.74% over the last week and switched with performance of -2.74% throughout past one month ...
Stock Digest (press release)
Don't Miss to Watch Stock: Alexion Pharmaceuticals (ALXN), FTS ...
Alexion Pharmaceuticals (ALXN) Technical Analysis: The price moved to 1.78% while comparing it with the average of 20 days and distanced ...


Back